2025-04-08 18:23:26
Latest Post
Godrej Properties delivers its highest ever quarterly and full year bookings
Poonawalla Fincorp Launches Shopkeeper Loan Business
Revolt Motors Expands to 200 Dealerships, Targets 400 by FY26
Sobha Ltd - Real Estate Operational Update - Q4 FY 2024-25
Lemon Tree Hotels signs a new property in DarjeelingStock Report
Jubilant Life Sciences Ltd reports consolidated net profit of Rs. 224.03 crore in Q2FY21
Posted On : 2020-11-04 15:37:32( TIMEZONE : IST )
JUBILANT LIFE SCIENCES LIMITED has reported financial results for the period ended September 30, 2020.
Financial Results (Q2 FY20-21) - QoQ Comparison
The company has reported total income of Rs.2382.17 crores during the period ended September 30, 2020 as compared to Rs.1901.05 crores during the period ended June 30, 2020.
The company has posted net profit / (loss) of Rs.224.03 crores for the period ended September 30, 2020 as against net profit / (loss) of Rs.88.01 crores for the period ended June 30, 2020.
The company has reported EPS of Rs.14.06 for the period ended September 30, 2020 as compared to Rs.5.53 for the period ended June 30, 2020.
| Financials | Q2 FY20-21 | Q1 FY20-21 | % Change |
| Total Income | ₹ 2382.17 crs | ₹ 1901.05 crs |  25.31% |
| Net Profit | ₹ 224.03 crs | ₹ 88.01 crs | 154.55% |
| EPS | ₹ 14.06 | ₹ 5.53 | 154.25% |
Financial Results (Q2 FY20-21) - YoY Comparison
The company has reported total income of Rs.2382.17 crores during the period ended September 30, 2020 as compared to Rs.2278.19 crores during the period ended September 30, 2019.
The company has posted net profit / (loss) of Rs.224.03 crores for the period ended September 30, 2020 as against net profit / (loss) of Rs.249.39 crores for the period ended September 30, 2019.
The company has reported EPS of Rs.14.06 for the period ended September 30, 2020 as compared to Rs.15.66 for the period ended September 30, 2019.
| Financials | Q2 FY20-21 | Q2 FY19-20 | % Change |
| Total Income | ₹ 2382.17 crs | ₹ 2278.19 crs | 4.56% |
| Net Profit | ₹ 224.03 crs | ₹ 249.39 crs |  -10.17% |
| EPS | ₹ 14.06 | ₹ 15.66 | -10.22% |
Financial Results (6 months ended FY 20-21) - YoY Comparison
The company has reported total income of Rs.4283.22 crores during the 6 months period ended September 30, 2020 as compared to Rs.4469.75 crores during the 6 months period ended September 30, 2019.
The company has posted net profit / (loss) of Rs.312.04 crores for the 6 months period ended September 30, 2020 as against net profit / (loss) of Rs.434.37 crores for the 6 months period ended September 30, 2019.
The company has reported EPS of Rs.19.59 for the 6 months period ended September 30, 2020 as compared to Rs.27.27 for the 6 months period ended September 30, 2019.
| Financials | Half-Year Ended FY20-21 | Half-Year Ended FY19-20 | % Change |
| Total Income | ₹ 4283.22 crs | ₹ 4469.75 crs | -4.17% |
| Net Profit | ₹ 312.04 crs | ₹ 434.37 crs | -28.16% |
| EPS | ₹ 19.59 | ₹27.27 | -28.16% |
Commenting on the Company's performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, CoChairman & Managing Director, Jubilant Life Sciences said: "Q2'FY21 has witnessed a substantial improvement over the previous quarter despite continued adverse impact of the COVID-19 pandemic in at least the first half of Q2.
The company's performance in the LSI business has been better in EBITDA as well as in margins both year-on-year as well as quarter-on-quarter due to good demand and improved pricing of select products. We maintained business continuity in all the manufacturing sites. DDDS segment witnessed strong year-on-year growth in revenues led by healthy demand from customers.
Pharma business performance improved substantially QoQ led by growth in CMO and Generics. Radiopharma continued to have a temporary negative impact due to COVID-19 related restrictions on hospital visitations. With the gradual opening of the US healthcare markets, demand conditions have started improving and Allergy business is already at Pre-COVID level during Q2'FY21. We continue to see new business opportunities in CDMO, Generics and Specialty Pharma segments.
With the strong demand recovery and new business sign-ups, we expect strong performance in our Pharma, LSI and DDDS businesses in the H2'FY21.
During H1'FY21, the Company reduced net debt on a constant currency basis by Rs 193 Crore."
Shares of JUBILANT LIFE SCIENCES LIMITED was last trading in BSE at Rs.695 as compared to the previous close of Rs. 716.85. The total number of shares traded during the day was 22418 in over 2236 trades.
The stock hit an intraday high of Rs. 730.35 and intraday low of 693.55. The net turnover during the day was Rs. 15762202.
